Join the discussion
Question 1/36
Company X has a patent for an anti-inflammatory drug that will expire in one year. In order to minimize the effect of the patent expiration, which is the BEST action for the company to take?
Correct Answer: C
Add Comments
- Other Question (36q)
- Q1. Company X has a patent for an anti-inflammatory drug that will expire in one year. In orde...
- Q2. Which question is pertinent to demonstrate a new pharmaceutical's effectiveness during eva...
- Q3. Which of the following is the MOST desirable timing and approach for a regulatory affairs ...
- Q4. During several monitoring visits, a clinical trial monitor identifies serious and repeated...
- Q5. The safety database for an anti-hypertensive drug consists of the following: * 461 patient...
- Q6. The regulatory authority in Country X issued a request for a mandatory product recall in C...
- Q7. What are the MOST important elements that global regulatory agencies want to know before a...
- Q8. One month prior to the anticipated approval date for your product, the marketing applicati...
- Q9. Which of the following is NOT required to be included in a marketing application?...
- Q10. A regulatory affairs professional is asked to review and update regulatory affairs SOPs. W...
- Q11. According to the GHTF, which of the following is NOT an exemption rule when evaluating the...
- Q12. According to WHO, what are the temperature and humidity conditions for a Zone IVb long- te...
- Q13. Which of the following double-blind clinical trial designs would be MOST appropriate for a...
- Q14. A company is developing a new medical device using innovative technology. Which of the fol...
- Q15. Which of the following situations does NOT require rapid communication to regulatory autho...
- Q16. The API used for an approved drug product conforms to international monograph specificatio...
- Q17. You discover that your company's top selling product in the last two years has been used o...
- Q18. Which of the following is NOT considered a serious adverse event in a cardiovascular clini...
- Q19. A company is considering the development of a medical device similar to those already avai...
- Q20. What is the LAST stage in the development of a quality risk management process for a medic...
- Q21. Which of the following statements regarding export regulations for an approved product is ...
- Q22. A company is developing a new line of products in an area that is new to the company. What...
- Q23. According to ISO 14971, what is the FIRST step when developing a risk management plan for ...
- Q24. A request was received from a regulatory authority asking the company to conduct product t...
- Q25. Company X encounters challenges in the global life cycle management of its medical devices...
- Q26. Which of the following criteria is MOST appropriate to define the animal species needed fo...
- Q27. A company is preparing the submission package for a drug to be registered in international...
- Q28. In addition to protection, what parameters MUST be considered when selecting the primary p...
- Q29. At the last internal audit, a regulatory affairs professional identified a need for a corr...
- Q30. In a distribution contract for high-risk medical devices, which of the following regulator...
- Q31. As a member of the product launch review committee, a regulatory affairs professional disc...
- Q32. According to the ICH guideline on GMP for API, to which of the following is the MOST strin...
- Q33. A regulatory authority announces an inspection of a regulatory affairs professional's faci...
- Q34. SOPs for preventive and corrective actions MUST include the procedure to eliminate which o...
- Q35. Which term does NOT describe the same concept as the others?...
- Q36. A materials supplier informs a company that it intends to stop supplying a material critic...
